Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Draft Nat'l Medical Expenditure Optimization Plan Announced
September 8, 2008
- Thalidomide Safety Control Criteria Discussed by Study Group
September 8, 2008
- TOPICS／Society to Prevent Uterocervical Cancer Inaugurated
September 8, 2008
- CDFS Committee Recommends Conditional Approval of Thalidomide
September 8, 2008
- Seven APIs Recommended for Switching to OTC Status
September 8, 2008
- 16 Products (11 APIs) Recommended for NHI Price Listing
September 8, 2008
- Use of CyberKnife II to Treat Tumors in Trunk of the Body Approved: Accuray
September 8, 2008
- BUSINESS NEWS IN BRIEF
September 8, 2008
- Terumo's DuraHeart Implanted in 1st Patient in US
September 8, 2008
- Yamato Expects Profits from Generics Delivery Service in 3 Years
September 8, 2008
- BD Enters Market for Cytodiagnostic Systems for Cervical Cancer
September 8, 2008
- Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
September 8, 2008
- Vascular Embolization Set for AVM Recommended for Approval
September 8, 2008
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
September 8, 2008
- R&D NEWS IN BRIEF
September 8, 2008
- Astellas Aims at Top Market Share in Japan
September 8, 2008
- 4 Healthcare Clusters to Focus on 4 Fields
September 8, 2008
- Prevent Recurrence of Stroke: Prof. Hasegawa
September 8, 2008
- No Evidence for Giving Priority to Iressa: CDFS
September 1, 2008
- Tokai Univ. to Settle Prices of Individual Drugs within Sept.
September 1, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…